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Abstract
We develop a general theory for three states of equilibrium of amyloid peptides: the monomer,
oligomer, and fibril. We assume that the oligomeric state is a disordered micelle-like collection of a
few peptide chains held together loosely by hydrophobic interactions into a spherical hydrophobic
core. We assume that fibrillar amyloid chains are aligned and further stabilized by ‘steric zipper’
interactions – hydrogen bonding and steric packing, in addition to specific hydrophobic sidechain
contacts. The model makes a broad set of predictions, consistent with experiments: (i) Similar to
surfactant micellization, amyloid oligomerization should increase with bulk peptide concentration.
(ii) The onset of fibrillization limits the concentration of oligomers in the solution. (iii) The average
fibril length vs. monomer concentration agrees with data on α-synuclein, (iv) Full fibril length
distributions follow those of α-synuclein, (v) Denaturants should ‘melt out’ fibrils, and (vi) Added
salt should stabilize fibrils by reducing repulsions between amyloid peptide chains. Interestingly,
small changes in solvent conditions can: (a) tip the equilibrium balance between oligomer and
fibril, and (b) cause large changes in rates, through effects on the transition-state barrier. This
model may provide useful insights into the physical processes underlying amyloid diseases.
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I. INTRODUCTION
What are the forces that stabilize aggregates of amyloid peptide molecules? This question
is of interest because of the putative role played by amyloid aggregation in diseases such as
Alzheimer’s, Parkinson’s, Mad Cow and type II diabetes [1]. Amyloid appears to aggregate
into at least two different states: amyloid oligomers, which are small few-chain soluble
disordered clusters, and fibrils, which are long many-chain highly structured β-sheet-like
aggregates. The view has recently emerged that the oligomers may be the toxic species,
not the fibrils, as had been expected because of the appearance of plaques in disease [2]. It
has been challenging to understand the physical principles of amyloid aggregation, in part
because of a lack of reductionist experimental model systems. In this breach, we believe
that simple models can help guide and interpret experiments.
The first challenge is to disentangle how much of amyloid formation can be explained by
equilibrium vs. kinetics. Often kinetics is easier to study experimentally because measuring
rates does not require finding conditions of reversibility. Yet, there is experimental evidence
of multiple stable states: monomers, oligomers, and fibrils, and perhaps a precursor to the
fibrillar state, called the protofilament [3]. We believe insights can be gained from first
understanding the underlying phase equilibria.
II. MODELING THE STATES OF AMYLOID AGGREGATION
We develop here a model of the equilibrium among the following states: (a) isolated
monomeric amyloid peptide molecules in solution, (b) few-chain noncovalent aggregates
(oligomers) of amyloid peptide molecules, (c) the single ‘macroscopic thread’ called a protofil-
ament, which is a noncovalent ordered assembly of many chains, and (d) the fibril, which
is a bundle of protofilaments. These states are shown schematically in Figs. 1 and 2. (In
this paper, ‘monomer’ refers to an individual peptide chain, not to a single amino acid in
a chain; see Fig. 2a) [3–5]. Our interest here is in peptides, such as Aβ, α-synuclein, and
IAPP, that do not have single-chain native folded structures, so our model below neglects
any possible additional equilibria with a native folded structure.
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A. Modeling the oligomer state
The oligomer state is shown in Fig. 2a. For Aβ aggregates, oligomers range in size from
trimers to hundreds of monomers [3–5]. We model the amyloid oligomer state as a disordered
spherical globule having a hydrophobic core containing N peptide chains. Each chain has L
amino acids. We approximate the free energy of oligomerization, ∆Foligo, from state A to B
in Figure 2, in terms of the transfer of the NL amino acids from water into the oligomeric
core as [6, 7],
∆Foligo =
∆FAB
kT
= −χNL, (1)
where kTχ is the free energy of transfer per amino acid and χ is the Flory-Huggins parameter,
averaged over the amino acid composition of the peptide and over the solvent accessibilities
of the various amino acids. Following recent work [8], we neglect the distinction between
interior and surface residues that was drawn in older models [6].
B. Modeling the protofilament and its nucleus
The β-sandwich motif, shown in Fig. 1c, is a common feature of amyloid aggregates
observed in NMR and X-ray structures [9–12]. Here, we assume that the basic structural
element comprising protofilaments and fibrils is the β-sandwich. Before describing our fibril
model, we first define our terminology for structures throughout this paper. A β-strand is
a single linear stretch of peptide chain. A β-sheet is comprised of two or more hydrogen-
bonded β-strands (see Fig. 1a,b). A β-sandwich is two planar β-sheets face-to-face (see Fig.
1c). For example, in the fibrillar state the Aβ molecule is a V -shaped β-hairpin comprised
of two beta strands. In amyloid fibrils, the β-sandwich is stabilized by H-bonds parallel to
the fibril axis and by hydrophobic and van der Waals interactions from the interdigitation
of side chains within the steric zipper between the two β-strands (see Fig. 1c) [9]. At a
given stage of fibrillization, we assume a β-sheet is composed of h β-strands. Each β strand
contributes b amino acids to the β-sheet. The sheet width b must satisfy b ≤ ℓ, where ℓ ≤ L
is the length of the β-strands in the mature fibril. At a given stage of fibril formation, the
total number of residues in the β state is m = 2bh, where the factor of two accounts for the
two sheets in the β-sandwich. The quantities b and h are shown schematically in Fig. 2c,d.
The quantity m serves as an order parameter for the extent of fibril formation.
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We treat the equilibrium between the oligomer (state B in Fig. 2), the fibril nuclei (states
C and D in Fig. 2), the protofilament (E in Fig. 2), and the full fibril (F in Fig. 2) in a way
that resembles the standard treatment of the helix-coil transition in peptides [13–17].
We call the states BCDE the fibril ordering pathway. The free energy is
∆FBCDE(m)
kT
= −χ(NL−m)−m ln gs −
√
m
2
ln γ, (2)
as a function of m, which can be regarded as an ‘order parameter’ or a ‘reaction coordinate’
along the route BCDE. m ranges from m = 0 when the system is fully disordered (i.e.,
fully in state B), to m = NL when the system is fully ordered in the β-state (i.e., fully in
state E). (So, in normalized form, a reaction coordinate could be expressed as ξ = m/NL).
The first term in Eq. 2 is the free energy of converting m of the NL amino acids from
their oligomeric disordered state, with a corresponding loss of the disordered micelle-like
hydrophobic interactions.
The second term in Eq. 2, −mkT ln gs, is the free energy of forming m pairwise steric
zipper interactions in the core of the fibril. gs is a dimensionless propagation equilibrium
coefficient. gs resembles the quantity s in helix-coil theories [13, 16], except that gs here
describes β structure, not α-helical structure. gs captures various types of interactions,
including conformational entropy, hydrogen bonds, steric packing, and ordered sidechain
hydrophobic interactions. A necessary condition for fibril formation is gs > 1. That is,
fibrils can only form when the sterically zipped state (hydrogen bonds, packing, and ordered
hydrophobic interactions) is more favorable than the monomeric state. The subscript s
here in gs indicates an interaction within a single β-sandwich, not between the different
β-sandwiches that make up a full fibril.
We treat fibrillar ordering as a surface/interior nucleation process. The third term in Eq.
2,
√
m/2 ln γ, is the free energy of initiating steric zipping at the edge of the β-sandwich
(a square having m/2 residues, has a perimeter with
√
m/2 residues). In our model, γ, is
a surface tension for forming the perimeter bonding. In the metaphor of helix-coil theories,
γ resembles σ, the helix-coil nucleation parameter. Fig. 2 shows that the edge of the β-
sandwich has 2b unsatisfied H-bonds, but only b unsatisfied hydrophobic contacts due to the
stagger between the two sheets. It is these missing hydrophobic and H-bond interactions that
account for why there should be a barrier, γ < 1, to nucleating the fibril. This nucleation
barrier free energy in Eq. 2 is maximal for b = ℓ. At the present stage of knowledge
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of microscopic structures, this square-shape approximation has the advantage of simplicity
and is adequate to capture the shift in the oligomer-fibril transition from hydrophobic to
combined hydrophobic and hydrogen bonding interactions [18].
This model gives insight into fibril formation rates. We compute the free energy of the
transition state by finding the maximum value of ∆Forder along the reaction coordinate m
using Equation 2. The transition state is at ∆F ‡ = (d∆Forder/dm)m⋆ = 0, so given by
∆∆F ‡
kT
=
∆Forder(m
⋆)−∆Forder(0)
kT
=
ln2 γ
8(ln(gs)− χ)
. (3)
Eq. 3 shows that the free energy barrier will be extremely sensitive since the quantity
ln(gs) − χ in the denominator will be small. ln gs and χ are dimensionless quantities of
order unity; their difference is small because the zipping free energy is expected to be only
slightly more favorable than amorphous hydrophobic interactions. Small variations in gs or
χ, at the level of single amino-acid changes or slight changes in solution conditions, could
change fibrillization rates by several orders of magnitude [19]. This provides a rationale
for understanding how a single mutation could transform a normal fibrillization rate, which
might be too slow to cause disease on a human lifetime, into a much faster fibrillization rate,
sufficient to cause disease during a human lifetime.
Our model of the amyloid nucleation process differs from classic nucleation mechanisms in
two respects: (1) ours involves a one-dimensional line tension, rather than a two-dimensional
surface tension [20], and (2) our ordering transition is from oligomers to fibrils, not from
monomers to aggregates, so our fibrillization mechanism is not driven by increasing the solu-
tion concentration of monomers. This is consistent with experiments showing that amyloid
nucleation is concentration-independent. The proposed explanation in the Nucleated Con-
formational Conversion (NCC) model [21] is that oligomeric chains must enter an activated
conformation to proceed to fibrils. In our model, the role of activation is played by the
entropically unfavorable steric-zipper nucleus.
C. Modeling the full fibril
In our model, a full fibril consists of p β-sandwich-motif protofilaments stacked and
bundled together. Fig. 2e shows such a fibril for p = 2. ∆FEF is the free energy of bundling
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protofilaments into fibrils,
∆Fbundling
kT
=
∆FEF
kT
= nLǫ = −nL ln
(
g
gs
)
(4)
where L remains the number of amino acids per peptide chain. n is the number of peptide
chains in the bundled fibril. g is the propagation constant for forming β structure in the
mature fibril. Eq. 4 gives − ln g = − ln gs+ ǫ, so − ln gs is the free energy of the interactions
within a single protofilament, and ǫ is the interaction energy holding the protofilaments
together. Because these bundling interactions occur only between a subset of residues on
the perimeter of the protofilament, we expect that g and gs will be similar.
Peptides are frequently folded within a fibril such that a single peptide chain contributes
multiple β-strands to the fibril. To account for this we introduce the parameters ℓ, the
length of each β-strand, and ns, the number of β strands formed by each peptide chain. For
example, peptides such as Aβ and IAPP that form a single hairpin in the mature fibril have
ns = 2. The quantity ns, defined such that L = nsℓ is shown in Fig. 3.
From Eq. 2 it is clear that each protofilament will incur a nucleation penalty −kTℓ ln γ
and each β-strand in the fibril will contribute a binding energy −kTℓ ln g. However, a more
convenient quantity is the binding energy per peptide −kTℓns ln g = −kTL ln g. The free
energy of a fibril consisting of n peptides is then
∆Fn
kT
=
∆FAF
kT
= − ln(γpℓgnL). (5)
The fibrillization index n must be greater than the minimum fibril size n0, however we will
find that the physical observables are insensitive to the precise value of n0. This is in contrast
to the oligomer size N which plays an important role in the phase behavior.
D. The monomer-oligomer-fibril assembly equilibrium
Now, we combine the free energies above into a grand canonical ensemble to determine
how the assembly equilibria depend on the concentration of peptide monomers in solution.
If the oligomeric state resembles a micelle, a reasonable approximation is that the oligomer
species is dominated by a single aggregation number, with free energy given by Eq. 1.
However, for the fibril, we assume a continuum of aggregation states having number n
peptide chains and a free energy given by Eq. 5. To compute the properties of the solution,
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we compute the binding polynomial [22],
Q = c1 + c
N
1 e
χNL + γpℓ
∑
n
cn1g
nL, (6)
In Eq. 6, c1 is the concentration of monomers, c
N
1 e
χNL is the concentration of oligomers, and
the final term is the sum over the concentrations of the fibrils of all possible lengths. The
total peptide concentration, c0 can be computed by using the concentration of each species
and summing the number of peptides in each species. Thus, c0 is written as
c0 =
dQ
d ln c1
= c1 +Nc
N
1 e
χNL + γpℓ
∞∑
n=n0
ncn1g
nL, (7)
where n0 is the smallest accessible fibril size.
The solution phase behavior is given by the peptide concentrations in each of three states:
monomer, c1; oligomer, coligo; and fibril, cfibril, where
coligo = Nc
N
1 e
χNL (8)
and
cfibril = γ
pℓ
∞∑
n=n0
ncn1g
nL (9)
are the component terms from Eq. 7. The three relative concentration quantities,
c1/c0, coligo/c0 and cfibril/c0 must sum to one. To compute the phase diagram we numer-
ically solve Eq. 7 for c1 at fixed values of c0, g, γ, and χ. The concentrations of peptides
in the fibril and oligomer states are then computed from Eqs. 8 and 9. Fig. 5 shows
the computed phase diagrams. The boundaries in Fig. 5 represent the conditions of equal
populations of the two corresponding states. In the Methods section we derive analytic
expressions for the phase boundaries. These are shown by the black lines in Fig. 5. The
model predictions are given in the following section.
III. RESULTS
The model defined in the previous section leads to a free energy landscape with features
schematically shown in Fig. 4. In the following we compute the phase equilibria resulting
from this landscape.
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A. The model predicts an amyloid triple point, a 3-state equilibria
Fig. 5 shows the phase diagram computed from Eq. 7. The x-axis shows the monomer
concentration. The y-axis shows ln g/χ, the ratio of the free energy for a steric zipper to
the free energy for amorphous hydrophobic aggregation. The model predicts three main
features. First, increasing the amyloid peptide concentration in solution leads to increased
aggregation (both oligomers and fibrils). Second, not surprisingly, at high peptide concen-
trations, changing solution conditions to favor steric zipping tips the balance from oligomers
toward fibrils. This phase equilibrium line is relatively flat, indicating that it is not very
dependent on monomer concentration. Third, there should be a triple point, a particular
monomer concentration and solution condition at which monomers, oligomers, and fibrils
are all present in equal populations.
The phase diagram can be closely approximated by comparing the critical fibril concen-
tration (CFC) to the critical oligomer concentration (COC) (see Methods). The lesser of
these two quantities determines the aggregate species that appears upon raising the peptide
concentration. However, if the COC is less than the CFC it may be possible to drive the
solution from the oligomer state to the fibril state by further raising the peptide concentra-
tion. This transition may be computed using the fibril-oligomer coexistence condition (see
Eqs. 24 and 38). The converse is not true; it is not possible to reach the oligomer phase from
the fibril phase by increasing the peptide concentration. This asymmetry arises from the
definitions of the critical concentrations. The CFC is defined by the radius of convergence of
Eq. 7, and thus it sets a hard limit on the achievable monomer concentration. On the other
hand, the monomer concentration will still rise, albeit weakly, upon reaching the COC, and
therefore it is possible for the monomer concentration to reach the CFC even after oligomers
have begun to form provided the CFC is not much greater than the COC.
B. When fibrils are stable, oligomers are not.
Interestingly, the model predicts a ‘sponge-like behavior’: under fibril-forming conditions,
amyloid peptide will be ‘soaked up’ into the fibrils and depleted from the oligomers. To see
this, substitute the CFC, Eq. 16, into Eq. 8, to get
coligo ∼ Ne
−LN(ln g−χ). (10)
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This small quantity, e−(ln g−χ) < 1, is raised to a large power, LN . So, unless χ and ln g
are closely matched, the concentration of the oligomeric state will be negligible under fibril-
forming conditions. The implication for disease is that if oligomers are toxic, promoting
fibril formation may deplete the toxins.
C. Fibril concentration increases as a nonlinear function of monomer concentra-
tion.
Fig. 6 compares the theory for how the fibril population, cfibril, depends on peptide con-
centration, to the experiments of Terzi et al. [23]. Since the N-terminal 11-16 residues of
Aβ are disordered [10, 24] in the fibril state, we take L = 26. In order to fit the data we
convert the experimental concentration cM (in Molar units) to the dimensionless concen-
trations required in our treatment. We use c = (cM/55.5)M . From that fit, we find that
−L ln g = −13.1 and −pℓ ln γ = 15.5 at the experimental conditions of 278 K and pH 7.4.
This is an order of magnitude stronger than the per-residue binding energy within native
proteins [8].
D. Fibril lengths undergo a ‘growth transition’ vs. monomer concentration.
Now we compute the distribution of fibril lengths. The probability P (n) that a fibril has
a length n is given by
P (n) =
cn1g
nL∑
i c
i
1g
iL
. (11)
What are the average fibril lengths? In the Methods section we show that the average
length scales as c
1/2
0 γ
−ℓp/2, in agreement with the concentration dependence found in ref-
erence [26]. Fig. 7 shows the predictions of Eq. 26 compared to the average fibril-length
measurements of van Raaij et al [25]. From the fit we find, gL, which determines the onset of
fibrillization and we find γℓp, which determines the fibril length. We obtain −L ln g = −15.5
and −ℓp ln γ = 32.3. In α-synuclein fibrils, it is found that p = 4, twice the value of Aβ
fibrils [25]. Accounting for this factor of two shows that the values of L ln g and ℓ ln γ are
quite similar to those determined for Aβ in the previous section. ns and ℓ are not yet known
for α-synuclein.
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Fig. 8 shows the prediction that the fibril lengths follow an exponential distribution; see
Eq. 26.
E. Denaturants destabilize the fibrils and oligomers
What is the effect of denaturants and osmolytes on amyloid aggregation? First, because
both oligomers and fibrils are stabilized by hydrogen bonding and hydrophobic interactions,
denaturants should ‘melt out’ amyloid aggregated states. A more subtle question is how
denaturants shift the oligomer-fibril equilibrium. Fig. 9 shows the model predictions (1)
that denaturants such as urea, not unexpectedly, should weaken hydrophobic and hydrogen
bonding interactions, disrupting aggregation, (2) that more denaturant is required to disrupt
aggregates if the amyloid concentration is high, and (3) that adding denaturant to fibrils
can drive the system into the oligomer state.
We note two additional points. First, in apparent contradiction to this prediction, de-
naturants are sometimes used to promote fibrillization, but that appears to be observed
exclusively in systems having a native folded state [27–29], unlike the systems we model
here. Second, the present model resolves a paradoxical result in the literature. Chen and
Glabe found that urea drove fibrils to ‘melt’ directly to monomers without passing through
the oligomer state [4]. In contrast, Kim et al. found that urea drove fibrils to melt to
oligomers, when then melted to monomers [30]. Our Fig. 9 gives an explanation: the
Aβ peptide concentrations used by Kim et al. were 3-10-fold greater than those used by
Chen and Glabe, shifting to a region of the phase diagram in which oligomers are a stable
intermediate phase.
F. Electrostatic repulsion destabilizes the fibrils
To treat the effects of pH and salt, we express the binding free energy
− L ln g(q, cs) = −L ln g0 +∆Fes(q, cs) (12)
in terms of g0, which accounts for the binding energy for a reference peptide having zero net
charge, and an electrostatic component, ∆Fes, which is the free energy of charging up the
peptides from their uncharged state to a net charge q in the presence of a salt concentration
cs. The latter is given quantitatively by Eq 43.
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Fig. 10 compares a simple calculation of the electrostatic repulsions with experimental
measurements of dependence of the critical concentration, which we identify with the theo-
retical quantity c
(f)
1 , on salt concentration. We compute a charge of q = −3.9 at pH 9.0 and
q = −2.8 at pH 7.4 for the Aβ peptide [31]. We treat each peptide as a cylinder of radius
R = 10nm [32] using Poisson-Boltzmann theory; see Eq. 43. Fig. 10 shows two experiments:
Klement et al. for pH 9 and Terzi et al. for pH 7.4. The sole fitting parameter in Fig. 10 is
−L ln g0 = −21.9. This corresponds to −L ln g = −15.5 under the pH 7.4, 5mM conditions
of Terzi et al. This represents a good agreement with our previous result of −L ln g = −13.1
given the extreme sensitivity of the electrostatic free energy at such low salt concentrations.
IV. CONCLUSION
We have described a general thermodynamic theory for the aggregation of short peptides
into globular and fibrillar aggregates. The model predicts two transitions: (1) a micelle-
like transition of monomeric peptides in solution to an oligomeric state involving a loose
hydrophobic core and a loss of translational entropy, and (2) a transition from the disordered
globular oligomeric state to an ordered β-structured fibrillar state, driven by tighter packing,
hydrogen bonding, and steric and hydrophobic interactions.
We find good agreement of the model with experiments on fibril concentrations, average
fibril lengths, and fibril length distributions vs. monomer concentrations. We find that
the phase boundaries and transition states are highly sensitive to small changes in solution
conditions and protein properties. Such sensitivities may be relevant to aggregation processes
in amyloid diseases.
V. METHODS
Critical fibril concentration (CFC)
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The concentration of peptides in the fibril state is given by the final term in Eq. 7
cfibril = γ
ℓp
∞∑
n=n0
ncn1g
nL (13)
= γℓpc1g
L d
d(c1gL)
∞∑
n=n0
cn1g
nL (14)
= γℓp
n0(1− c1g
L)(c1g
nsℓ)n0 + (c1g
L)n0+1
(1− c1gL)2
. (15)
The sum in Eq. 13 converges when the argument is less than unity, therefore the monomer
concentration must satisfy c1 < g
−L if the bulk concentration is to remain finite. This radius
of convergence defines a concentration
c
(f)
1 ∼ g
−L, (16)
which may be interpreted as the CFC for the fibril solution. For c1 much less than this value
the concentration of monomers in the fibril state cfibril is strongly suppressed by the factor
γℓp(c1g
L)n0 . However, as c1 approaches g
−L the fibril concentration diverges. In this regime
we can write c1g
L = 1− δ and the fibril concentration becomes
cfibril ≃ γ
ℓp (1− n0δ)(1 + n0δ − δ)
δ2
(17)
= γℓp
c1g
L +O(δ2)
(1− c1gL)2
, (18)
which demonstrates that cfibril is insensitive to the lower limit n0.
Note that our definition for the CFC differs from that given in reference [26].
Critical oligomer concentration (COC)
Due to the importance of oligomers in disease progression, we would like to calculate
the concentration of oligomers both in the presence and absence of fibrils. In the presence
of fibrils we can approximate the concentration of peptides in the oligomer state, coligo, by
using the CFC in the second term of Eq. 7 since the monomer concentration varies little in
the vicinity of the fibril CFC
coligo ∼ Ng
−LNeχLN . (19)
This expression is only valid provided eχ < g. If this condition is not satisfied, then Eq.
2 is a monotonically increasing function of m meaning the oligomer state has a lower free
energy per peptide than a fibril of any length. In this case no fibrils will be formed, and the
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solution will be an equilibrium mixture of oligomers and monomers. We define the COC to
be the concentration where the oligomer and monomer states have equal occupancies. Using
the appropriate terms from Eq. 7 we find the COC given by
c
(COC)
1 =
(
e−χNL
N
)1/(N−1)
. (20)
Fibril-oligomer boundary
The boundary between the fibril and oligomer phases is defined, for points suitably re-
moved from the monomer phase, by the condition cfibril = coligo ≃ c0/2. Using Eqs. 18 and
19 we have
c0/2 = γ
ℓp c1g
L
(1− c1gL)2
(21)
c0/2 = Nc
N
1 e
χNL. (22)
Eq. 21 yields a recursive formula for c1, which to lowest order gives
c1 ≃ g
−L(1−
√
2γℓp/c0) (23)
which can be combined with Eq. 22 to yield a condition for the phase boundary
ln g
χ
=
NL ln g
ln
(
c0
2Ng−L
)
−N ln
(
1−
√
2γℓp/c0
) . (24)
This expression is plotted with long dashes in Fig. 5
Average fibril length
The critical concentrations for fibril and oligomer formation, c
(f)
1 and c
(o)
1 are notably
lacking a dependence on the nucleation parameter γ. While this parameter has little effect
on the relative stability of the fibril and oligomer phases, we expect that it will play a large
role in determining the equilibrium lengths of mature fibrils. To see this we consider a system
that is deep within the regime where fibrils are the dominant species so that c0 ≃ cfibril.
Using Eq. 18 we find
c1 ≃ g
−L(1−
√
γℓp/c0). (25)
The jth moment of the fibril length distribution is given by
〈nj〉 =
γℓp
∑
n n
jcn1g
nL
γℓp
∑
n c
n
1g
nL
(26)
=
(
(c1g
L)n0
1− c1gL
)−1(
c1g
L d
d(c1gL)
)j (
(c1g
L)n0
1− c1gL
)
. (27)
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The average length is given by the first moment j = 1
〈ℓ〉 = n0 +
c1g
L
1− c1gL
(28)
∼ c
1/2
0 γ
−ℓp/2 + const, (29)
where Eq. 25 has been used to extract the scaling behavior.
The lack of a dependence on g in this scaling relation is a result of an approximation
based on c0 ≫ c
(f)
1 . When this assumption is satisfied the large majority of protein is in the
fibril state, and the problem of determining the fibril lengths is reduced to a question of fibril
breakage statistics. Since each breakage incurs a statistical penalty γℓp, the functional form
of Eq. 29 is not surprising (the factor of two in the exponent is a result of the degeneracy
of breakage points). For systems near the onset of fibrillization c0 ≃ c
(f)
1 the fibril lengths
depend sensitively on g and Eq. 26 must be used to model the lengths.
Denaturants
Denaturants destabilize the folded states of proteins by weakening hydrophobic interac-
tions and peptide-peptide H-bonds relative to peptide-solvent H-bonds [33]. To capture the
effect of denaturants on the interaction free energy quantities g and γ, we use
kT ln gc = kT (ln g − a0cd)
kT ln γc = kT (ln γ + a0cd), (30)
where gc and γc are the propagation parameters in the presence of denaturant, cd is the
denaturant concentration and a0 is a constant describing the destabilizing effect of the
osmolyte. This form reflects the fact that the denaturant weakens the H-bonds captured
in g, but also reduces the fibril end free energy − ln γ, which arises largely from unsatisfied
H-bonds.
Using Eqs. 16, 20, and 30 we can compute how the critical concentrations will shift as
a function of denaturant concentration. At the onset of fibrillization we have c0 = c
(f)
1 , so
from Eqs. 16 and 30 we have
ln c1 = −L ln gc (31)
= −L(ln g − a0cd), (32)
which can be solved for cd to give the phase boundary
cd =
ln c0 + L ln g
La0
. (33)
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Similarly, for the oligomer state we write
χc = χ− a1cd (34)
where a1 has been introduced to reflect the fact that since the oligomers are more dependent
on hydrophobic interactions and less dependent on H-bonds for stability, and therefore, the
destabilization coefficient will, in general, be different. The onset of oligomerization may be
determined from Eq. 20
c0 =
(
e−NL(χ−a1cd)
N
)1/(N−1)
, (35)
which can be rearranged to yield
cd =
1
a1
(
χ+
(N − 1) ln c0 + lnN
NL
)
. (36)
The fibril-oligomer boundary can be derived from Eqs. 21 and 22
ln c0/2N = NL(χ− a1cd)−NL(ln g − a0cd), (37)
where we have dropped the correction term in Eq. 21. In Fig. 9 we take a1 = a0/2 reflecting
our expectation that the hydrophobic interactions stabilizing the oligomer are less affected
by the presence of denaturant than the H-bonds stabilizing the fibril [8, 34]. However, the
particular choice of a0/2 is for illustration purposes. With this approximation for a1 Eq. 37
becomes
cd =
2
a0NL
(
ln
c0
2N
−NL(χ + ln g)
)
. (38)
Based on denaturation studies, we expect that a0 = 0.022M
−1 for urea and 0.042 for
guanidinium [8]. Using our estimates of L ln g = 13.1 and ℓp ln γ = −15.5 (in the absence
of urea) for Aβ from our previous analysis of fraction fibril as a function of concentration
(Fig. 6) we can predict the fibril fraction as a function of urea using Eq. 30 without a fit
parameter. Our prediction is compared with the experimental data in Table I.
Electrostatics
To compute Fes we approximate the fibril as a smooth cylinder of radius R and uniform
charge density. The linear charge density may be computed by noting that the average
charge per β-strand is q/ns and there are 2p strands per layer in the fibril.
To determine the peptide charge as a function of pH, we use
q =
acidic residues∑
i
−
10pH−pKai
1 + 10pH−pKai
+
basic residues∑
i
+
10pKai−pH
1 + 10pKai−pH
, (39)
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Experiment [30] Theory
[urea] Oligomer fraction Fibril fraction Fibril fraction
0.4M 0 0.37 0.30
2 0.37∗ 0.03
4 0.2 0 10−3
6 0.22 0 10−5
TABLE I: Computed fraction of peptide in the fibril phase compared to the data of Kim et al.
[30].
∗ Aggregate fraction was observed to be a combination of fibrils and oligomers.
where the pKas of the amino acids are taken from Ref. [31]. So, the charge density on each
peptide-molecule cylinder is ρ = 2qp/nsa, where a = 4.7 A˚ is the spacing between amino
acids.
We then solve for the electrostatic potential ψ using the Poisson-Boltzmann equation
ǫ
1
r
∂
∂r
r
∂ψ
∂r
= −e(c+ − c−), (40)
where the ion concentrations are c± = cse
∓eψ/kT . In the linearized (Debye-Huckel) approxi-
mation, Eq. 40 has the solution
ψ(r) =
2q
2πRaǫκK1(κR)
K0(κr), (41)
however, we use the numerical solution of the nonlinear Eq. 40 as the dimensionless potential
eψ/kT can reach values in excess of unity at the low salt concentrations we consider. Here
κ−1 is the Debye length, defined via κ2 ≡ 2e2c0/ (ǫkBT ). At infinite dilution the appropriate
boundary conditions are ψ′(R) = −ρ/2πǫR and ψ(∞) = 0, but for the purposes of the
numerical solver we employ the outer boundary condition ψ′(d) = 0 corresponding to a
solution of fibrils separated by an average distance 2d. We take d = R+5κ−1 (see Fig. 11).
For d≫ κ−1 the influence of the outer boundary condition will be minimal.
Once we have computed ψ, we get the electrostatic free energy density of the peptide
cylinder as [35]
f =
ǫ
2
(
dψ
dr
)2
+ kT (c+ ln(c+/cs) + c− ln(c−/cs)− c+ − c− + 2cs). (42)
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The first term in Eq. 42 is the electrostatic energy stored in the electric field, and the
remaining terms account for the translational entropy of the ions in the screening layer. We
then compute the free energy per peptide using
∆Fes = 2π
nsa
2p
∫ ∞
R
f(r)rdr (43)
where r is the radial coordinate perpendicular to the axis of the cylinder.
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FIG. 1: Assembly hierarchy of amyloid fibrils shown in atomistic cartoon representation (left) and
schematically with β-sheets as blocks (right). a) A single β sheet comprised of parallel β-strands.
b) β-sheet observed along fibrillization axis. c) Assembled β-sandwich (protofilament) consisting
of two β-sheets. Note the steric zipper interactions shown as interdigitating side chains (left) and
as a green layer (right). d) Mature fibril consisting of p = 2 protofilaments.
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FIG. 2: Model of amyloid aggregation equilibria. Each black line indicates the peptide backbone.
Each red line shows one hydrogen bond. A) Isolated peptide monomers in solution. B) Oligomeric
assembly of a few peptide chains. C) Nucleus of β-sheet structure. The peptide backbone runs
perpendicular to the fiber axis. D) Post-critical nucleus structure having more β-structure. E)
Protofilament is a single long thread of β-structure consisting of a β-sandwich, two β-sheet planes
face-to-face. F) Full fibril, a bundle of protofilaments, shown here containing p = 2 protofilament
threads.
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(b)
(c)
ns = 2
ns = 4
(a) ns = 1
FIG. 3: Schematic representation of the parameter ns. Here each peptide chain contributes a)
one, b) two, and c) four β-strands to the fibril. For clarity, adjacent peptide chains are shown in
alternating colors.
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FIG. 4: Schematic representation of the free energy landscape described by our model at low
(left), intermediate (middle), and high peptide concentration (right). Labels correspond to the
states shown in Fig. 2. At low concentrations the monomer state (A) is the free energy minimum,
while at high concentrations the fibril (F) is the minimum. At intermediate concentrations the
solution is an equilibrium of monomers and oligomers (B).
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FIG. 5: Phase diagram for peptides with p, ns = 1, ℓ = 15, ln g = 0.6, and ln γ = −2 as a function
of peptide concentration and ln g/χ. Green =c1/c0 (monomers). Blue = coligo/c0) (oligomers).
Red =cfibril/c0 (fibrils). Lines depict phase boundaries computed from Eq. 24 (long dashes), Eq.
20 (short dashes), and Eq. 16 (solid).
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FIG. 6: Plot of cfibril as a function of the bulk peptide concentration compared to CD data of
Terzi et al. for Aβ1−40 [23]. L = 26, ns = 2, p = 2, g = 1.66 and γ = 0.54
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FIG. 7: Average length of fibrils vs. peptide concentration, and compared to experiments on
α-synuclein [25].
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FIG. 8: Comparison of the computed fibril length distribution as a function of the bulk peptide
concentration to the experimental distributions of α-synuclein [25].
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FIG. 9: Phase diagram for Aβ as a function of peptide concentration and urea concentration.
The colors represent monomers (green), oligomers (blue), and fibrils (red). N = 4, χNL = 36.4
[4], and all other parameters are identical to Fig. 6. This diagram explains a discrepancy between
the experiments of Chen and Glabe, where the black line indicates denaturation. They found no
intermediate oligomers. For the Kim experiments, denaturation is indicated by the white line; they
observed oligomeric intermediates.
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FIG. 10: Predicted solubility of Aβ40 as a function of salt concentration and net peptide charge.
Data points at q = 3.9 are from [32] and the point at q = 2.8 is from [23].
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FIG. 11: Cylindrical fibril geometry used to solve Eq. 40. Fibrils are taken as cylinders of radius
R separated by a distance 2d. Red lines denote individual β-strands (shown here for a fibril with
p = 2). Horizontal disks show the spacing h between β-strand layers within the fibril. Eq. 40
is solved from surface of the reference fibril (center), out to a distance d (outer cylinder) with
the boundary condition ψ′(d) = 0 reflecting the symmetry of the electric potential between the
cylinders.
26
